Withdrawal Symptoms from Invega (Paliperidone)
Yes, Invega can cause withdrawal symptoms when discontinued, including nausea, vomiting, insomnia, anxiety, agitation, and movement disorders, particularly if stopped abruptly. The FDA label specifically warns that neonates exposed to Invega in the third trimester may experience extrapyramidal and/or withdrawal symptoms 1.
Documented Withdrawal Symptoms
When stopping Invega or other atypical antipsychotics, patients may experience:
Somatic symptoms:
- Nausea and vomiting
- Diarrhea
- Diaphoresis (sweating)
- Rhinorrhea (runny nose)
- Myalgia (muscle pain)
- Paresthesias (tingling sensations)
Neuropsychiatric symptoms:
- Anxiety and agitation
- Restlessness
- Insomnia
- These symptoms can be prodromal to psychotic relapse 2
Movement disorders:
- Withdrawal-emergent dyskinesias (abnormal involuntary movements)
- These may represent "covert dyskinesia" (masked tardive dyskinesia that becomes apparent only after drug withdrawal) or true withdrawal dyskinesia that resolves spontaneously within 6-12 weeks 3
Clinical Context and Mechanism
The withdrawal phenomena occur due to receptor rebound effects. Invega blocks dopamine D₂ and serotonin 5-HT2A receptors, along with histaminergic, muscarinic, and adrenergic receptors 4. When the drug is discontinued, particularly abruptly, the sudden loss of receptor blockade can trigger cholinergic overactivity and dopamine-acetylcholine imbalance in the basal ganglia 3.
Critical Distinction
Distinguish withdrawal symptoms from psychotic relapse: Increased anxiety, agitation, restlessness, and insomnia can herald psychotic relapse, but the temporal relationship to dose reduction or discontinuation is key to identifying true withdrawal symptoms 2. If these symptoms appear within days to 2 weeks of stopping Invega, consider withdrawal rather than immediate relapse.
Practical Management Recommendations
To minimize withdrawal symptoms when discontinuing Invega:
- Avoid abrupt discontinuation - taper gradually when clinically feasible
- Consider bridging with concomitant medications such as benzodiazepines for anxiety/insomnia or anticholinergic agents for movement symptoms 4
- Monitor closely for the first 2-4 weeks after discontinuation
- Educate patients and families about potential withdrawal symptoms so they can report them early 1
Important Caveat
For Invega Sustenna (long-acting injectable): The extended-release formulation continues releasing medication for months after the last injection 5, 6. This means withdrawal symptoms may be delayed or attenuated compared to oral formulations, but monitoring should extend for several months post-discontinuation. The loading dose strategy can also cause prolonged adverse effects due to sustained high drug levels 7.